Pharmagreen Biotech (Pharmagreen Biotech) Gross Margin % : 0.00% (As of Jun. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Pharmagreen Biotech Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Pharmagreen Biotech's Gross Profit for the three months ended in Jun. 2023 was $0.00 Mil. Pharmagreen Biotech's Revenue for the three months ended in Jun. 2023 was $0.00 Mil. Therefore, Pharmagreen Biotech's Gross Margin % for the quarter that ended in Jun. 2023 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.

The historical rank and industry rank for Pharmagreen Biotech's Gross Margin % or its related term are showing as below:

PHBI' s Gross Margin % Range Over the Past 10 Years
Min: 0 Med: 0 Max: 50
Current: 50

During the past 7 years, the highest Gross Margin % of Pharmagreen Biotech was 50.00%. The lowest was 0.00%. And the median was 0.00%.

PHBI's Gross Margin % is ranked better than
56.59% of 986 companies
in the Drug Manufacturers industry
Industry Median: 46.405 vs PHBI: 50.00

Pharmagreen Biotech had a gross margin of N/A% for the quarter that ended in Jun. 2023 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Pharmagreen Biotech was 0.00% per year.

Pharmagreen Biotech Gross Margin % Historical Data

The historical data trend for Pharmagreen Biotech's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmagreen Biotech Gross Margin % Chart

Pharmagreen Biotech Annual Data

Trend

Apr08

Apr09

Sep18

Sep19

Sep20

Sep21

Sep22

Gross Margin %

Get a 7-Day Free Trial

Pharmagreen Biotech Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Gross Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Pharmagreen Biotech's Gross Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Pharmagreen Biotech's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharmagreen Biotech's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pharmagreen Biotech's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Pharmagreen Biotech's Gross Margin % falls into.

Pharmagreen Biotech Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Pharmagreen Biotech's Gross Margin for the fiscal year that ended in Sep. 2022 is calculated as

Gross Margin % (A: Sep. 2022 )	=	Gross Profit (A: Sep. 2022 )	/	Revenue (A: Sep. 2022 )
	=	0	/	0
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(0 - 0)	/	0
	=	N/A %

Pharmagreen Biotech's Gross Margin for the quarter that ended in Jun. 2023 is calculated as

Gross Margin % (Q: Jun. 2023 )	=	Gross Profit (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	0	/	0.001
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(0.001 - 0)	/	0.001
	=	N/A %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Pharmagreen Biotech (OTCPK:PHBI) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Pharmagreen Biotech had a gross margin of N/A% for the quarter that ended in Jun. 2023 => No sustainable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Pharmagreen Biotech Gross Margin % Related Terms

Thank you for viewing the detailed overview of Pharmagreen Biotech's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmagreen Biotech (Pharmagreen Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pharmagreen Biotech Inc (OTCPK:PHBI) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

112 North Curry Street, Carson, NV, USA, 89703

Website

https://www.pharmagreen.ca

Pharmagreen Biotech Inc is a biotech science company with specialized products and services in the cannabis industry. The company plans to produce and sell tissue culture plantlets and cannabis oil. Its line of nutraceutical products is a proprietary blend of therapeutic plants and mushrooms. It is developing its business model beyond just cannabis, and is focused on near term revenues from its proprietary blend of therapeutic plants and fungi, a nutraceutical wellness product. Utilizing the Company's expertise in plant genetics, Its transgenic program uses the newest technology available to research and create nutraceuticals, protein-based vaccines, and daily supplements with the potential to improve lives and address a wide variety of disease conditions.